Job Description

Job Code:
19-013

Torrance, US-CA  90502

Employment Status:
FT 100 % for 40-hours per week (regular full-time benefits)

# of Openings:
1

Department:
Infectious Disease-1138

Minimum education requirements:
Ph.D.

Salary Range:
Based on Qualifications & Experience

Last Updated:
2/19/19 3:15 PM

The Ibrahim laboratory in the Division of Infectious Diseases at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center are seeking applications for a Postdoctoral Researcher. The lab focuses on vaccine developments against healthcare-associated infections such as those caused by Candida and Staphylococcus aureus infections using antigens with structural and functional homology among these two pathogens. Our laboratories are part of an Infectious Diseases group that constitutes more than 15 senior researchers studying the pathogenesis of fungal and bacterial infections with emphasis on host-pathogen interactions, biofilm formation, host defense and immunopathogenesis. Recent publications related to the topic of vaccine development against Candida and S. aureus infections include:

  1. Ibrahim AS, Luo G, Gebremariam T, Lee H, Schmidt CS, Hennessey Jr. JP, French SW, Yeaman MR, Filler SG, Edwards Jr. JE (2013).  NDV-3 Protects Mice From Vulvovaginal Candidiasis Through T- and B-Cell Immune Response. Vaccine 31: 5549– 5556. PMCID: PMC3866209.
  2. Efficacy and Immune Mechanisms of the NDV-3 Vaccine in a Murine Model of MRSA Skin / Skin Structure Infection.  Proc Natl Acad Sci U S A. pii: 201415610. [Epub ahead of print] PMCID: PMC4280579.
  3. Uppuluri P, Singh S, Alqarihi A, Schmidt CS, Hennessey, Jr. JP, Yeaman MR, Filler SG, Edwards Jr, JE, Ibrahim AS. Human Anti-Als3p antibodies are surrogate markers of NDV-3A vaccine efficacy against recurrent vulvovaginal candidiasis. Frontiers in Immunology. 15 June 2018; 9:1349 doi: 10.3389/fimmu.2018.01349.
  4. Uppuluri P, Singh S, Alqarihi A, Schmidt CS, Hennessey, Jr. JP, Yeaman MR, Filler SG, Edwards Jr, JE, Ibrahim AS. Human Anti-Als3p antibodies are surrogate markers of NDV-3A vaccine efficacy against recurrent vulvovaginal candidiasis. Frontiers in Immunology. 15 June 2018; 9:1349 doi: 10.3389/fimmu.2018.01349.

  5. Uppuluri P, Singh S, Alqarihi A, Schmidt CS, Hennessey, Jr. JP, Yeaman MR, Filler SG, Edwards Jr, JE, Ibrahim AS. Human Anti-Als3p antibodies are surrogate markers of NDV-3A vaccine efficacy against recurrent vulvovaginal candidiasis. Frontiers in Immunology. 15 June 2018; 9:1349 doi: 10.3389/fimmu.2018.01349.

There is currently an opening to optimize a dual antigen vaccine that targets heathcare-infections caused by multidrug resistant pathogens.The position is available in the summer of 2019 up to 4 years and requires experience in immunology. Basic skills of molecular biology techniques including cloning, gene disruption, recombinant protein production, are highly desirable. We are committed to furthering the careers of junior investigators. Therefore, proficiency in verbal and written use of the English language including the ability to write peer reviewed papers and grants are required.Motivated PhDs and/or M.D.’s, including females and minorities, are encouraged to submit their curriculum vitae, reprints/preprints, and a statement of research accomplishments and interests to Ashraf Ibrahim at ibrahim@labiomed.org.  

Application Instructions

Please click on the link below to apply for this position. A new window will open and direct you to apply at our corporate careers page. We look forward to hearing from you!

Apply Online